多发性硬化治疗风险容忍度调查
该研究邀请北美多发性硬化研究委员会注册队列及美国国家多发性硬化协会成员中的多发性硬化患者填写问卷,评估其对 hypothetical 治疗相关真实世界风险的容忍度。结果显示患者对进行性多灶性白质脑病(PML)和肾损伤的风险容忍度最低(1:1,000,000),对甲状腺损伤和感染的风险容忍度最高(1:1,000)。男性、较年轻者、残疾程度较高者及正在接受治疗者对各类风险的容忍度更高。
要点
- PML和肾损伤的风险容忍度最低,均为1:1,000,000。
- 甲状腺损伤和感染的风险容忍度最高,均为1:1,000。
- 男性、年轻、残疾程度高及正在治疗者风险容忍度更高。
核心结论
- 多发性硬化患者对治疗相关风险的容忍度范围广泛,性别、年龄、残疾程度和当前疾病修饰治疗使用与风险容忍度相关。
研究设计与样本
- 邀请北美研究委员会注册在线队列和美国国家多发性硬化协会的多发性硬化患者完成问卷,评估对 hypothetical 治疗真实世界风险的容忍度。
主要发现
- PML和肾损伤的风险容忍度最低,为1:1,000,000;甲状腺损伤和感染的风险容忍度最高,为1:1,000。
- 男性、较年轻个体和残疾程度较高的参与者对所有风险场景的容忍度更高。
- 当前正在接受多发性硬化治疗者比未接受任何治疗者容忍度更高。
- 接受输注治疗者对所有风险容忍度高,接受注射治疗者容忍度较低。
临床怎么用
- 临床决策中应结合患者的性别、年龄、残疾程度及当前治疗类型,个体化沟通多发性硬化治疗的风险容忍度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine tolerance to various risk scenarios associated with current multiple sclerosis (MS) therapies. METHODS: People with MS from the North American Research Committee on Multiple Sclerosis Registry's online cohort and the National Multiple Sclerosis Society were invited to complete a questionnaire on tolerance to real-world risks associated with a hypothetical therapy. Multiple risks levels were presented, including skin rash, infection, kidney injury, thyroid injury, liver injury, and progressive multifocal leukoencephalopathy (PML). RESULTS: Both PML and kidney injury had the lowest risk tolerance (RT) at 1:1,000,000, and thyroid and infection risks had the highest tolerance at 1:1,000. Men, younger individuals, and participants with greater disability reported a higher tolerance to all risk scenarios. Those who were currently taking an MS therapy reported higher tolerance than those not taking any therapy. Participants taking infusion therapies reported high tolerance to all risks, and those taking injectables reported a lower tolerance. CONCLUSION: People with MS displayed a wide range of RT for MS therapies. Our study identified sex, age, disability, and current disease-modifying therapy use to be associated with RT.
引用
- Fox RJ, Cosenza C, Cripps L, et al. A survey of risk tolerance to multiple sclerosis therapies. Neurology. 2019. PMID: 30867272. doi:10.1212/WNL.0000000000007245
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。